PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Dinutuximab Beta→

Dinutuximab Beta PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
Not available
Molecular formula
C6432H9916N1716O2014S48
Molecular weight
~146800 g/mol
Drug class
Chimeric anti-GD2 monoclonal IgG1 antibodyantineoplastic immunotherapy
Mechanism of action
Binds the GD2 disialoganglioside expressed on neuroblastoma cells and triggers complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity, leading to tumour-cell lysis.
Indications / reported uses
  • Treatment of high-risk neuroblastoma in patients aged 12 months and older who previously received induction chemotherapy and achieved at least a partial response, as part of post-consolidation therapy; use with required combination agents and product-specific conditions

Sources: EMA EPAR — Qarziba · EMA product information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Dinutuximab Beta PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Dinutuximab Beta Permitted Daily Exposure (PDE) report (the Dinutuximab Beta PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Dinutuximab Beta Occupational Exposure Limit (OEL) report (the Dinutuximab Beta OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.